181 |
1α,25-Dihydroxyvitamin D<sub>3</sub> Reverses Nitric Oxide and Peroxynitrite Imbalance in Dysfunctional Endothelium: A Nanomedical ApproachKhan, Alamzeb 21 September 2015 (has links)
No description available.
|
182 |
Mechanisms of nitric oxide control in endothelial and cardiac dysfunctionJoshi, Mandar S. 24 August 2005 (has links)
No description available.
|
183 |
Studies on the heme oxygenase-1 pathway and anti-angiogenic factors in preeclampsia and endothelial protectionRamma, Wenda January 2011 (has links)
The endothelium plays a pivotal role in the maintenance of vascular homeostasis and its dysregulation promotes vascular complications. This thesis proposes that heme oxygenase-1 (HO-1), an anti-inflammatory enzyme with antioxidant properties, is endothelial protective factor that prevents endothelial injury induced by cisplatin or activated neutrophils. Specifically, this thesis aimed to test (i) that overexpression of HO-1 prevents cisplatin-induced endothelial injury and suppresses caspase activity; (ii) whether neutrophil-endothelial cell activation resulted in the release of soluble Flt-1 (sFlt-1) and soluble endoglin (sEng), the two anti-angiogenic factors known to induce the clinical signs of preeclampsia; (iii) whether HO-1 prevented activated neutrophils from stimulating the release of these factors from the endothelium; (iv) the relative contribution and the co-dependency of neutrophil activation and anti-angiogenic growth factors in preeclampsia where systemic endothelial dysfunction is known to occur. This thesis shows that cisplatin inhibited human umbilical vein endothelial cells (HUVEC) metabolism as measured by MTT assay and resulted in the release of placenta growth factor (PlGF). Immunoblotting confirmed that cisplatin increased cleaved caspase-3 expression in HUVEC. These effects of cisplatin were attenuated in HUVEC infected with adenovirus encoding HO-1 and the effects were exacerbated when HO-1 was silenced by siRNA. Furthermore, cisplatin stimulated PlGF release was suppressed by the overexpression of HO-1. In addition, HO-1 overexpression inhibited angiogenesis as determined by vascular endothelial growth factor-induced capillary tube formation on Matrigel coated plates. Thus these studies indicate that agents which upregulate HO-1 could increase the effectiveness and tolerability to cisplatin in cancer treatment. Although neutrophils are early contributors to endothelial cell activation, no studies have determined their contribution to the release of sFlt-1 and sEng. We therefore investigated the effect of activated neutrophils on the release of sFlt-1 and sEng in endothelial/neutrophil co-cultures and in the circulation of women with normal pregnancy and preeclampsia. LPS-mediated neutrophil activation stimulated the release of sEng but not sFlt-1 from endothelial cells in culture. In the absence of neutrophils, overexpression of HO-1 in HUVEC downregulated the release of sEng. In contrast, HO-1 overexpression failed to inhibit the release of sEng in the presence of activated neutrophils. The release of sEng by activated neutrophils-endothelial cell cocultures appears to be mediated by metalloproteinases (MMP) as the broad-spectrum MMP inhibitor (GM6001) attenuated sEng release. Clinical studies demonstrated that sEng, pro-inflammatory interleukin-6 (IL-6) and the soluble markers of neutrophil activation (α-defensins and calprotectin) were all elevated in women with preeclampsia. We identified a direct correlation between neutrophil activation and IL-6 release. However, no correlation could be established between these factors and sEng release in preeclampsia. Hence, these results provide compelling clinical evidence to show that the increase in neutrophil activation and IL-6 release during preeclampsia are unlikely to significantly contribute to the clinical signs of preeclampsia as they fail to correlate directly with the anti-angiogenic factors, which form the final common pathway to the clinical signs of preeclampsia and systemic endothelial dysfunction.
|
184 |
Recombinant adeno-associated virus mediated vascular endothelial growth factor gene therapy induces mandibular condylar growthDai, Juan., 戴娟. January 2007 (has links)
published_or_final_version / abstract / Dentistry / Doctoral / Doctor of Philosophy
|
185 |
Role of cytokines in reduced implantation following excessive ovarian stimulationMakkar, Guneet. January 2005 (has links)
published_or_final_version / abstract / Obstetrics and Gynaecology / Doctoral / Doctor of Philosophy
|
186 |
Nanoscale Feature Composite: An Ensemble Surface for Enhancing Cardiovascular Implant EndothelializationTran, Phat L. January 2011 (has links)
The establishment and maintenance of functional endothelial cells (ECs) on an engineered surface is central to tissue engineering. As the field advances, the role of cellular mechanisms, particularly the adhesive interaction between the surface of implantable devices and biological systems, becomes more relevant in both research and clinical practice. Knowledge of these interactions can address many fundamental biological questions and would provide key design parameters for medical implants. It has been shown that EC functionality and adhesivity, crucial for the re-endothelialization process, can be induced by nanotopographical modification. Therefore, the goal of this dissertation research was to develop an ensemble surface composing of nanoscale features for the enhancement of endothelial cell adhesion. Without adhesion, subsequent vital mechanism involved in cell alignment, elongation or spreading, proliferation, migration, and ECM proteins deposition will not occur.Experiments in support of this goal were broken down into three specific aims. The first aim was to characterize and develop a size-dependent self-assembly (SDSA) nanoarray of Octamer transcription factor 4 as a demonstration to the fabrication of nanoscale feature surface. This nanoparticle array platform was a pilot studied for the second aim, which was the development of an ensemble surface of nanoscale features for endothelial cell adhesion. The third aim was to evaluate and assess EC response to the ensemble surface.Hence, we developed an ensemble surface composed of nanoscale features and adhesive elements for EC adhesivity. By using shear stress as a detachment force, we demonstrated greater cell retention by the ensemble surface than uniform controls. Adhesive interactions and cellular migration through integrin expressions, which are critical to tissue development and wound healing process was also observed. Furthermore, cell viability was relatively sustainable, as indicated by the low expression of apoptotic signaling molecules. The findings presented within this dissertation research can be applicable to blood-contact medical implants and possess the potential for future clinical translation.
|
187 |
The ARP 2/3 complex mediates endothelial barrier function and recoveryBelvitch, Patrick, Brown, Mary E., Brinley, Brittany N., Letsiou, Eleftheria, Rizzo, Alicia N., Garcia, Joe G.N., Dudek, Steven M. 02 1900 (has links)
Pulmonary endothelial cell (EC) barrier dysfunction and recovery is critical to the pathophysiology of acute respiratory distress syndrome. Cytoskeletal and subsequent cell membrane dynamics play a key mechanistic role in determination of EC barrier integrity. Here, we characterizAQe the actin related protein 2/3 (Arp 2/3) complex, a regulator of peripheral branched actin polymerization, in human pulmonary EC barrier function through studies of transendothelial electrical resistance (TER), intercellular gap formation, peripheral cytoskeletal structures and lamellipodia. Compared to control, Arp 2/3 inhibition with the small molecule inhibitor CK-666 results in a reduction of baseline barrier function (1,241 +/- 53 vs 988 +/- 64 ohm; p < 0.01), S1P-induced barrier enhancement and delayed recovery of barrier function after thrombin (143 +/- 14 vs 93 +/- 6 min; p < 0.01). Functional changes of Arp 2/3 inhibition on barrier integrity are associated temporally with increased intercellular gap area at baseline (0.456 +/- 0.02 vs 0.299 +/- 0.02; p < 0.05) and thirty minutes after thrombin (0.885 +/- 0.03 vs 0.754 +/- 0.03; p < 0.05). Immunofluorescent microscopy reveals reduced lamellipodia formation after S1P and during thrombin recovery in Arp 2/3 inhibited cells. Individual lamellipodia demonstrate reduced depth following Arp 2/3 inhibition vs vehicle at baseline (1.83 +/- 0.41 vs 2.55 +/- 0.46 mm; p < 0.05) and thirty minutes after S1P treatment (1.53 +/- 0.37 vs 2.09 +/- 0.36 mm; p < 0.05). These results establish a critical role for Arp 2/3 activity in determination of pulmonary endothelial barrier function and recovery through formation of EC lamellipodia and closure of intercellular gaps.
|
188 |
Angiogenesis in endometriosis : the role of circulating angiogenic cells and the endometriumWebster, Katie Elizabeth January 2012 (has links)
Endometriosis is a common cause of subfertility and pelvic pain, affecting up to 10% of women of reproductive age. It is characterised by the presence of endometrial-like tissue outside the uterus. The development of the disease is still poorly understood and, currently, the diagnosis relies on visualisation of typical lesions during surgery. There is great interest in identifying biomarkers to assist in diagnosis and disease management. Blood vessel development is known to be a crucial feature of endometriosis, but the mechanisms involved in angiogenesis are not well described for this disease. Most vessel development relies on the proliferation and migration of pre-existing endothelial cells. However, there may also be roles for cells derived from peripheral blood (circulating angiogenic cells) and surrounding stromal cells. In this thesis, the contribution of these different cell types to vessel development in endometriosis is assessed. In chapter 2, a robust protocol was optimised to identify circulating angiogenic cells (CACs) with flow cytometry. The reliability of the protocol was verified, and the level of these cells was found not to fluctuate with the menstrual cycle in healthy women (P=0.279, F=1.359, 3 d.f.). In chapter 3, levels of CACs in women with and without endometriosis were found to be equivalent (0.0835% ± 0.0422 compared to 0.0724% ± 0.0414), demonstrating that they have no use as a disease biomarker. In chapter 4, isolation and culture of endothelial cells from the endometrium was attempted. However, a pure culture of endometrial endothelial cells could not be obtained, which may be due to contamination by other cell types or cellular transdifferentiation. Finally, in chapter 5, the contribution of endometrial stromal cells to vessel development was considered. Stromal cells were found not to differentiate towards an endothelial cell phenotype, but were able to participate in tube formation assays. However, the presence of endometriosis did not influence this behaviour.
|
189 |
Endothelial activation in experimental metastasis modelsFerjancic, Spela January 2011 (has links)
The majority of cancer related deaths occur due to the invasive growth of metastatic lesions. In the early stages of metastasis, circulating cell interact with the endothelial cells to establish at a distant site. In inflammation endothelial activation results in induction of adhesion molecules on the endothelium that participate in the homing of leukocytes. Because of the interactions of metastatic cells with the endothelium, the question was whether some of the characteristic molecules of endothelial activation were induced during metastasis. In vivo pulmonary metastatic models were used to characterize the expression profile of endothelial activation. Immunohistochemistry identified VCAM-1 to be induced on the pulmonary endothelium following tumour cell arrest. VCAM-1 upregulation was not observed prior to tumour cells arrest or within the first hours. In contrast, tumour cell arrest appeared to be required for endothelial activation, arguing against a mechanism analogous to leukocyte homing. The upregulation of VCAM-1 upon tumour cell arrest corresponded with the initiation of platelet clot formation around the tumour cell and recruitment of leukocytes to the site, both previously shown to be essential for metastasis. Disruption of both phenomena, either through genetic or pharmacological manipulation, demonstrated that in contrast to the recruited leukocytes, platelets were involved in inducing endothelial activation. Another protein investigated was VAP-1. In contrast to VCAM-1, central to VAP-1 adhesive function is its enzymatic activity. Blocking the functions of either molecule highlighted their role in facilitating the recruitment of the leukocyte population to the tumour cell. Disruption of which led to a significant attenuation of metastasis. While VCAM-1 and VAP-1 function appears critical in the early steps of metastasis, their inhibition had no effect at later stages of pulmonary colonization.
|
190 |
A role for endothelial cells in regenerative and personalized medicinePeacock, Matthew Richard 22 January 2016 (has links)
REGENERATIVE MEDICINE: VASCULARIZED SKELETAL MUSCLE
Tissue engineering is a compelling strategy to create replacement tissues and in this study, skeletal muscle. One major hurdle in the field is how to vascularize large tissue-engineered constructs exceeding the nutrient delivery capability of diffusion. Endothelial colony forming cells and mesenchymal progenitor cells form blood vessels de novo and were co-injected with satellite cells in Matrigel, an extracellular matrix, or PuraMatrix, a synthetic hydrogel. Our approach focused on the ability of bioengineered vascular networks to induce murine and human satellite cells to differentiate and form organized skeletal muscle when injected. We found that perfused human blood vessels were formed in both Matrigel and PuraMatrix and that murine satellite cells differentiated and formed organized myotubes with striations, indicative of adult skeletal muscle. Mesenchymal progenitor cells also induced differentiation of satellite cells in vitro. Human Satellite cells, however, did not show signs of differentiation in either Matrigel or Puramatrix. These data have provided a proof of concept of engineering vascularized skeletal muscle using murine satellite cells.
INDUCTION OF CARDIOMYOGENESIS
The heart's regenerative capabilities are not robust enough to repair the amount of damaged tissue from myocardial infarction. A novel approach to relieve the ischemia is to deliver cells with vasculogenic ability, endothelial colony forming cells and mesenchymal progenitor cells, to assemble de novo blood vessels and support recovery of cardiomyocytes. In our study, we used an in vitro transwell system that prevent cell contact, but allow diffusion of soluble factors to investigate if endothelial colony forming cells or mesenchymal progenitor cells secrete factors that induce cardiomyogenesis. We found that neonatal rat cardiomyocyte proliferation is enhanced in the presence of endothelial colony forming cells and mesenchymal progenitor cells; however, presence of these cells without fetal bovine serum is not sufficient to initiate cardiomyogenesis.
PERSONALIZED THERAPY FOR RENAL CELL CARCINOMA TESTING IN AN ENDOTHEIAL CELL MODEL
Sunitinib and Pazopanib are both tyrosine kinase inhibitors with high specificity for vascular endothelial growth factor receptor 2 and are used in the treatment of Renal Cell Carcinoma to inhibit angiogenesis. Recent clinical findings suggest that a subset of the population with a single nucleotide polymorphism in vascular endothelial growth factor receptor 2 respond better to Pazopanib treatment. We used a standard in vitro angiogenesis assay, endothelial cell proliferation, to test the effects of the single nucleotide polymorphism on responsiveness to Sunitinib and Pazopanib. We found that cells containing the polymorphism are more sensitive to Pazopanib than Sunitinib, confirming the clinical finding. We also analyzed the inhibition of phosphorylated vascular endothelial growth factor receptor 2 and confirmed drug activity on the phosphorylated protein. These findings could have personalized clinical implications for the 3% of the population with the polymorphism.
|
Page generated in 0.06 seconds